AddLife Development AB
ABActiveOrg 5564908373Birger Jarlsgatan 43, 111 45 StockholmWholesale of pharmaceutical and medical goods· NACE 4646Est. 1994 · 32 years old4 employees
Loading company…
Overview
AddLife Development AB is a Swedish AB based in Stockholm, operating in the Wholesale of pharmaceutical and medical goods sector. Incorporated in 1994, the company has 4 employees and reported revenue of SEK 110.8m in its latest annual filing.
Revenue 2025
0.1B SEK
+13% vs 2024
EBITDA margin
−4.3 %
−83% vs 2024
Net profit 2025
0.4B SEK
+218% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
31.2 %
WeakAmong the 40% lowest rated companies in the industry
20212025
Liquidity ratioCurrent assets ÷ Short-term debt
4.6×
StrongAmong the 30% highest rated companies in the industry
20212025
Return on assets (ROA)Net profit ÷ Total assets × 100
4.6 %
AverageAround the average of companies in the same industry
20212025
EBITDA — year on year
SEK thousandsKey figures
Annual report 2025| Revenue | 0.1B SEK | +13% |
| EBITDA | -0B SEK | -83% |
| Net profit | 0.4B SEK | +218% |
| Total assets | 8.4B SEK | +9% |
| Equity | 2.6B SEK | +30% |
| Employees | 4 | — |
Company information
Legal name
AddLife Development AB
Org number
5564908373
Legal form
Aktiebolag
NACE code
Founded
15 August 1994 · 32 years
Share capital
SEK 100,000
Employees
4 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firmanbeträffande löpande förvaltningsåtgärder
Company purpose
Föremål för bolagets verksamhet är att marknadsföra, sälja och distribuera laboratorieprodukter avsedda för in vitro-metoder nationellt och internationellt, att tillhandahålla tjänster inom detta område samt inneha och förvalta företag, ävensom driva annnan därmed förenlig verksamhet.
(no translation available)
Contact
Address
Birger Jarlsgatan 43, 111 45 Stockholm
Email
info@add.life
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), AddLife Development AB reported revenue of SEK 110.8m, an increase of 13% on the year before. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net profit of SEK 386.9m, and the EBITDA margin stood at -4.3%.
At the end of 2025, equity financed 31.2% of the balance sheet, and current assets covered short-term debt 4.6 times.
Financials
Revenue
SEK millionsEBITDA
SEK thousandsIncome statement
SEK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 110,751 | 98,272 | 89,240 | 87,675 | 66,436 |
| Staff expenses | -17,491 | -11,772 | — | — | — |
| EBITDA | -4,794 | -2,618 | -1,629 | 618 | 3,017 |
| Depreciation & amort. | -0 | -0 | -61 | -1,622 | -2,229 |
| EBIT | -4,794 | -2,618 | -1,690 | -1,004 | 788 |
| Net financials | 123,760 | -351,573 | -413,292 | -102,323 | 206,546 |
| Profit before tax | 440,035 | -326,694 | -434,334 | 114,257 | 359,536 |
| Tax | -53,096 | -43 | -2,050 | -184 | -11,731 |
| Net profit | 386,939 | -326,737 | -436,384 | 114,073 | 347,805 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
SEK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 8,358,331 | 7,655,423 | 7,876,991 | 8,592,467 | 7,923,383 |
| Equity | 2,603,635 | 1,998,361 | 2,080,012 | 1,286,239 | 1,172,166 |
| Long-term debt | 5,657,000 | 5,560,240 | 5,704,648 | 7,237,777 | 6,646,680 |
| Short-term debt | 97,696 | 96,822 | 92,331 | 49,951 | 86,037 |
| Total debt | 5,754,696 | 5,657,062 | 5,796,979 | 7,287,728 | 6,732,717 |
Financial ratios
5-year trendEBITDA margin
-4.3 %
20212025
Equity ratio
31.2 %
WeakAmong the 40% lowest rated companies in the industry
20212025
Return on equity
14.9 %
StrongAmong the 40% highest rated companies in the industry
20212025
Net profit margin
349.4 %
Very strongAmong the 10% highest rated companies in the industry
20212025
Asset turnover
0.01×
Very weakAmong the 20% lowest rated companies in the industry
20212025
Debt / equity
2.21×
WeakAmong the 40% lowest rated companies in the industry
20212025
Sector performance
27 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Gross marginVery weak
Among the 20% lowest rated companies in the industry
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginWeak
Among the 30% lowest rated companies in the industry
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginVery strong
Among the 10% highest rated companies in the industry
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Strong
Among the 40% highest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Average
Around the average of companies in the same industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Strong
Among the 40% highest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Average
Around the average of companies in the same industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioWeak
Among the 30% lowest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioStrong
Among the 30% highest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioVery strong
Among the 20% highest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioVery weak
Among the 10% lowest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityVery strong
Among the 10% highest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalVery weak
Among the 20% lowest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioVery weak
Among the 20% lowest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioWeak
Among the 40% lowest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioWeak
Among the 40% lowest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityWeak
Among the 40% lowest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityWeak
Among the 40% lowest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtAverage
Around the average of companies in the same industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtWeak
Among the 40% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageWeak
Among the 40% lowest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtVery weak
Among the 20% lowest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginAverage
Around the average of companies in the same industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverVery weak
Among the 20% lowest rated companies in the industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Equity to contributed capitalVery strong
Among the 10% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityStrong
Among the 30% highest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtAverage
Around the average of companies in the same industry
The size of this year's increase or decrease in the company's debt.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Annual reports & filings
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AC Chief Executive Officer | Chief Executive Officer | 2022 |
FO Chief Auditor | Chief Auditor | 2026 |
Former (3)
MA Chief Executive Officer | Chief Executive Officer | 2022 – 2022 |
HE Chief Auditor | Chief Auditor | 2023 – 2026 |
PJ Chief Auditor | Chief Auditor | 2022 – 2023 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
AC Board of Directors | Board of Directors | 2022 |
PM Board of Directors | Board of Directors | 2022 |
FO Chairman | Chairman | 2022 |
Former (2)
EK Chairman | Chairman | 2022 – 2022 |
MA Board of Directors | Board of Directors | 2022 – 2022 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
AddLife AB100%
AddLife Development AB (this company)Remi Gmbh100% ownedHepro AS100% ownedBionordika (Denmark) A/S100% ownedVision Ophthalmology Holding One Group100% ownedMediplast A/S100% ownedMediplast S.R.L.100% ownedBionordika (Finland) Oy100% ownedMba Incorporade S.L.100% ownedEdge Medical Ltd.100% ownedTriolab Oy100% ownedTechnipro Pulmomed Pty Ltd100% ownedBestic AB100% ownedOldco 2769 AB100% ownedImmuno Diagnostics Oy100% ownedMediplast AS100% ownedBonsailab S.L.U.100% ownedBionordika Bergman AS100% ownedMediplast Australien100% ownedMba Italia, S.R.l100% owned
Biomedica Italia S.R.L.100% ownedEuroclone S.P.A.100% ownedBiomedica Medizinprodukte Gmbh100% ownedPrimacy Healthcare 21 Limited100% ownedTriolab A/S100% ownedRopox A/S100% ownedFenno Medical Oy100% ownedLab-Vent Controls A/S100% ownedBio-Connect B.V.100% ownedFunksjonsutstyr AS76% ownedDach Medical Group Holding Ag100% ownedMediplast Gmbh100% ownedMediplast Sataside Oy100% ownedHolm & Halby A/S100% ownedMba Incoporado S.L.100% ownedFischer Medical Aps100% ownedHospidana A/S100% ownedTriolab AS100% ownedBiocat Gmbh100% ownedMediplast Iberia Sl100% ownedMediplast Holding Aps100% ownedMaia Holding B.V. - Bioconnect Group100% ownedTriolab Baltic Oü100% ownedMediplast Benelux B.V.100% ownedBergman Diagnostika AS100% ownedVäino Korpinen Oyy100% ownedTriolab A/S100% ownedMediplast Iberia SL100% ownedMediplast Benelux B.V.100% ownedEuroclone S.P.A.100% ownedTechnipro Pulmomed Pty LTD100% ownedDach Medical Group Holding Ag100% ownedBergman Labora AB100% ownedBiolin Scientific AB100% ownedBiolin Scientific Ltd100% ownedBiolin (Shanghai) Trading Co., Ltd100% owned
Biolin Scientific Oy100% ownedBiolin Scientific Oy100% ownedBiolin Scientific LTD100% ownedBiolin (shanghai) Trading Co., LTD100% owned
Hepro Care AB100% ownedJK Lab Nordic AB100% ownedCamanio AB100% ownedMba Incorporade S.L.100% ownedBonsailab S.L.U.100% ownedTriolab Oy100% ownedMediplast GmbH100% ownedBio-Connect B.V.100% ownedMba Italia, S.R.L100% owned
Biomedica Italia S.R.L.100% ownedMba Incoporado S.L.100% ownedHolm & Halby A/S100% ownedMediplast S.R.L.100% ownedVision Ophthalmology Holding One Group100% ownedBiomedica Medizinprodukte GmbH100% ownedEdge Medical LTD.100% ownedFunksjonsutstyr AS76% ownedVäino Korpinen Oyy100% ownedMediplast Australien100% ownedOpitek International ApS100% ownedTriolab Baltic Oü100% ownedPrimacy Healthcare 21 Limited100% ownedMediplast AS100% ownedRopox A/S100% ownedHospidana A/S100% ownedBionordika (denmark) A/S100% ownedMaia Holding B.V. - Bioconnect Group100% ownedImmuno Diagnostics Oy100% ownedTriolab AS100% ownedHepro AS100% ownedRemi GmbH100% ownedBergman Diagnostika AS100% ownedTriolab Aktiebolag100% ownedLabRobot Products Aktiebolag100% ownedBioNordika (Sweden) AB100% ownedV-Tech AB100% ownedFischer Medical ApS100% ownedLab-Vent Controls A/S100% ownedBionordika (finland) Oy100% ownedMediplast A/S100% ownedMediplast AB100% ownedSvan Care AB100% ownedFenno Medical Oy100% ownedBoard network connections
Board members of AddLife Development AB also hold positions in 296 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Helena Eva Marie Nilsson | Chief Auditor | 110 companiesMany roles |
| Per Jonas Eriksson | Chief Auditor | 83 companiesMany roles |
| Fredrik Olof Ingvar Göransson | Chief Auditor | 55 companiesMany roles |
| Martin Almgren | Chief Executive Officer | 20 companiesMany roles |
| Eva Kristina Willgård | Chairman | 11 companiesMany roles |
| Anna Christina Rubenhag | Chief Executive Officer | 9 companiesMany roles |
| Fredrik Olof Dalborg | Chairman | 5 companies |
| Peter Mikael Simonsbacka | Board of Directors | 3 companies |
Frequently asked questions
What is the Org number of AddLife Development AB?
AddLife Development AB is registered with Bolagsverket / SCB under Org 5564908373.
What is the revenue of AddLife Development AB?
AddLife Development AB reported revenue of SEK 110.8m in 2025.
How many employees does AddLife Development AB have?
AddLife Development AB employs 4 people as of the latest annual report.
Who is the CEO of AddLife Development AB?
Anna Christina Rubenhag is the CEO of AddLife Development AB, in role since 2022.
Who is the chairman of AddLife Development AB?
Fredrik Olof Dalborg chairs the board of AddLife Development AB, in role since 2022.
Where is AddLife Development AB headquartered?
AddLife Development AB's registered address is Birger Jarlsgatan 43.